EDD (E3 isolated by differential display), located at chromosome 8q22.3, is the human orthologue of the Drosophila melanogaster tumour suppressor gene 'hyperplastic discs' and encodes a HECT domain E3 ubiquitin protein-ligase. To investigate the possible involvement of EDD in human cancer, several cancers from diverse tissue sites were analysed for allelic gain or loss (allelic imbalance, AI) at the EDD locus using an EDD-specific microsatellite, CEDD, and other polymorphic microsatellites mapped in the vicinity of the 8q22.3 locus. Of 143 cancers studied, 38 had AI at CEDD (42% of 90 informative cases). In 14 of these cases, discrete regions of imbalance encompassing 8q22.3 were present, while the remainder had more extensive 8q aberrations. AI of CEDD was most frequent in ovarian cancer (22/47 informative cases, 47%), particularly in the serous subtype (16/22, 73%), but was rare in benign and borderline ovarian tumours. AI was also common in breast cancer (31%), hepatocellular carcinoma (46%), squamous cell carcinoma of the tongue (50%) and metastatic melanoma (18%). AI is likely to represent amplification of the EDD gene locus rather than loss of heterozygosity, as quantitative RT-PCR and immunohistochemistry showed that EDD mRNA and protein are frequently overexpressed in breast and ovarian cancers, while among breast cancer cell lines EDD overexpression and increased gene copy number were correlated. These results demonstrate that AI at the EDD locus is common in a diversity of carcinomas and that the EDD gene is frequently overexpressed in breast and ovarian cancer, implying a potential role in cancer progression.
Introduction
Previously, we identified EDD (E3 isolated by Differential Display) (Callaghan et al., 1998) , the human orthologue of the Drosophila melanogaster 'hyperplastic discs' gene (hyd) (Mansfield et al., 1994) . Both genes encode large proteins of approximately 300 kDa that contain conserved carboxy terminus HECT domains, indicating they function as E3 ubiquitin protein ligases (Huibregtse et al., 1995; Schwarz et al., 1998) . Mutagenesis studies (Mansfield et al., 1994) define an apparent tumour suppressor role for hyd in Drosophila by demonstrating its critical requirement in control of cell proliferation during development. Some mutations result in imaginal disc hyperplasia and adult sterility due to germ cell defects, while the null hyd phenotype is lethality in the pupal or larval stages. Defects in hedgehog signalling may contribute to these phenotypes (Lee et al., 2002) .
These properties of hyd suggest the potential involvement of EDD in regulating mammalian cell proliferation and hence in human tumorigenesis or tumour progression. This possibility is reinforced by an implied role for EDD in DNA damage signalling. A recent study found that topoisomerase IIb binding protein (TopBP1) is ubiquitinylated and targeted for proteosomal degradation by EDD (Honda et al., 2002) . TopBP1 colocalizes with BRCA1 at stalled replication forks, evidence that TopBP1 functions in the DNA damage response (Makiniemi et al., 2001) . EDD also interacts in a DNA damage-dependent manner with the calcium-and integrin-binding protein (CIB) (Henderson et al., 2002) . This protein in turn interacts with DNAdependent protein kinase, which also functions in DNA damage pathways (Wu and Lieber, 1997) .
EDD has been localized by fluorescence in situ hybridization (FISH) to chromosome band 8q22.3 (Callaghan et al., 1998) and recent genomic sequencing shows that the gene has a centromeric orientation with its first exon placed at 8q23 (Genbank Accession AP002852). Many studies have reported chromosomal aberrations on 8q but used sparse and imprecisely mapped markers. Only recently have more detailed studies of 8q been conducted. In genome-wide comparative genomic hybridization (CGH) and microsatellite scans, gene amplification at 8q is commonly observed in a wide variety of cancers (van Dekken et al., 1997; Knuutila et al., 1998) and has been attributed to increases in 8q copy number or to amplification of the MYC oncogene (8q24.12) and surrounding regions (Wong et al., 1999; Yokota et al., 1999) . However, there is evidence in many tumour types for other foci of amplification and several genes have been identified as potential 8q oncogenes (Balleine et al., 2000; Nupponen et al., 2000) .
As a first step to test whether EDD might have a role in human cancer, microsatellite allelotyping was used to determine whether chromosomal aberrations within 8q22.3-8q24.13, a region spanning the EDD locus, are common in a range of human cancers. These data provided evidence for frequent allelic imbalance (AI) at the EDD locus which in breast cancer cell lines was associated with mRNA overexpression and amplification of the EDD gene. The subsequent demonstration of protein overexpression in a significant proportion of breast and ovarian cancers provided supporting evidence for the common amplification and overexpression of the EDD gene in cancer.
Results

Microsatellite analysis
The frequency of AI surrounding the EDD locus (8q22. 3) was investigated in malignant ovarian tumours, breast cancers, hepatocellular carcinomas, metastatic melanomas and squamous cell carcinomas of the anterior tongue using nine microsatellites shown in Figure 1 . As CEDD (CA repeat within EDD) and 586F18b are located within introns of the EDD gene, it can be assumed that chromosomal loss or gain involving these alleles is equivalent to loss or gain of an EDD allele.
Within the complete cancer set, the frequency of AI in the narrow region of 8q under study was considerable: 60% (83/139 informative cases) had AI at one or more markers. The individual frequencies (cases with AI/ informative cases) were D8S326 47/103 (46%), CEDD 38/90 (42%), D8S257 29/96 (30%), D8S300 27/69 (39%), D8S545 28/87 (32%) and D8S85 24/90 (27%) ( Table 1) . Notably, CEDD and the neighbouring 8q22.3 marker D8S326 had the greatest frequency of AI. In addition, as can be seen from the following data, 30-40% of those cancers that have chromosomal aberrations at the CEDD microsatellite show no involvement of one or more microsatellites at the telomeric end of the region studied. This indicates that AI at the EDD locus often occurs independently of more extensive aberrations in these cancers (i.e. loss or gain of the whole chromosome arm or coamplification with the MYC proto-oncogene).
Ovarian cancer
The ovarian tumour set comprised several cancer subtypes (predominantly mucinous, endometrioid and serous), borderline tumours and nonmalignant benign tumours. Within the carcinomas, 48% (34/71) displayed AI at one or more markers in the region (Figure 2) . In marked contrast, benign and borderline tumours exhibited only 1/23 and 1/5 cases of AI, respectively, involving several microsatellites but not CEDD or DS8257 (Table 1) . Owing to the low frequency of involvement of 8q22.3-8q23.3 in benign and borderline tumours, they were omitted from the following analysis.
Several cancers had AI across all informative markers, consistent with large chromosomal aberrations, for example, cases 63, 114 and 154. However, of interest are those cancers where AI is present at the EDD locus but not at the more telomeric markers (e.g. cases 14, 22, 32 and 211; Figure 2 ). This suggests that an important region of chromosomal aberration is located close to the EDD locus. Indeed a central finding of this study is the observation in serous cancers that CEDD was the microsatellite most commonly affected by AI (16/22, 73% of informative cases). This very high frequency of involvement differs significantly from that for the more telomeric markers D8S545 (6/18, 33%, Po0.01) or D8S85 (5/14, 36%, Po0.01). In fact, when serous cancers are compared to other ovarian cancers, CEDD is the only microsatellite for which AI differs significantly between the two groups (P ¼ 0.0018). However, no correlation was apparent between AI at any locus and tumour grade and stage, either within the entire set of cancers or the serous subtype (data not shown).
Hepatocellular carcinoma, squamous cell carcinoma of the tongue and metastatic melanoma
In all three cancer types, AI was common (Table 1) with 74, 33 and 47% of cancers displaying AI of at least one microsatellite respectively.
Of 19 hepatocellular carcinomas studied, four had regions of imbalance that included CEDD but did not extend continuously telomeric to 8q22.3 (Figure 1a) . Similarly, analysis of 17 metastatic melanomas (Table 1) identified three cancers where the region of AI did not involve markers telomeric to 8q22.3 (example shown in Figure 1 ). Of the 12 squamous cell tongue carcinomas analysed four had AI involving 8q22.3 (CEDD and/or D8S326), and in three of these cancers the region of imbalance did not extend to the most telomeric markers D8S85 and D8S545 (example shown in Figure 1 ). Thus, in these three cancer types, the chromosomal region at Positions of polymorphic microsatellites were identified from the Genome Data Base (GDB) (http://gdbwww.gdb.org/). Microsatellites CEDD and 586F18b are encoded in introns of EDD. The EDD gene is located at 8q22.3 (Callaghan et al., 1998) and MYC at 8q24.12 (GDB). (b) Microsatellite analysis of allelic imbalance from normal hepatocellular tissue and hepatocellular carcinoma from patient 8 (a). Allelic imbalance was seen for microsatellites D8S326, CEDD, D8S545 and D8S85. Arrows indicate significant increase (430%) in proportion of allele indicated 
Breast cancer
For microsatellite analysis of breast cancer DNA, three additional microsatellites were introduced to provide more information about AI at the EDD locus (586F18b) and at the telomeric region of 8q around MYC (8q24.12). (D8S198 and MYC-PCR.3). As with the other cancer types studied, AI was common on 8q with 16/24 (67%) breast cancers displaying AI at one or more markers (Table 1) . CEDD or 586F18b were involved in 6/16 (38%) of informative cases. Commonly, AI involved MYC-PCR.3 or D8S198, consistent with the frequent amplification of MYC in breast cancer, but in the majority of cancers AI was not continuous from 8q22.3 to 8q24 (examples shown in Figure 1 ). These data support previous suggestions that there are foci for AI on chromosome 8q in breast cancer distinct from and centromeric to MYC (Nesbit et al., 1999; Nupponen et al., 1999 Nupponen et al., , 2000 .
EDD mRNA expression in breast cancers
EDD mRNA expression levels were determined by quantitative RT-PCR in 41 breast cancers, and in matched normal breast tissue controls for 14 of these cases (Figure 3a) . Although the majority of cancers expressed EDD mRNA within the normal range, a significant number 11/41 (27%) had higher expression. Elevated expression was even more apparent when cancers were compared to their matched normal tissue controls, such that 6/14 (43%) cancers had a 4four-fold increase in EDD expression, including one cancer with a 159-fold increase (Figure 3a , inset).
EDD, p53R2 and CA II mRNA expression and genomic copy number in breast cancer cell lines
Using quantitative RT-PCR, mRNA expression levels were determined for EDD and two genes near the same locus (p53 ribonucleotide reductase (p53R2) and carbonic anhydrase II (CA II)) in 18 breast cancer cell lines. The corresponding DNA copy numbers for the three genes were determined by quantitative PCR. For EDD, these values were consistent with those determined by FISH analysis which was performed in four cell lines. There was a strong trend for EDD to be overexpressed at the mRNA level when EDD was amplified at the DNA level (Figure 3b ). Almost all cell lines where EDD was overexpressed had amplified EDD at the genomic level (7/8), whereas EDD was rarely overexpressed when the gene copy number was two or less. This was also true for the expression of p53R2, the gene adjacent to EDD at chromosome position 8q23.1. All cell lines where p53R2 was overexpressed had increased p53R2 gene copy number ( Figure 3b ). The relative expression of EDD and p53R2 was significantly correlated (R 2 ¼ 0.62, Po0.0001) suggesting a similar mechanism of overexpression for both genes. In contrast, the expression of CA II, located at 8q22, showed no relationship with DNA copy number (data not shown), with 15/18 cell lines having less than 10% of the expression levels of CA II mRNA of 184 normal breast epithelial cells.
EDD protein expression in breast and ovarian cancers
EDD protein levels were determined by immunohistochemistry in nine specimens of normal breast tissue, 46 breast carcinomas and 94 serous ovarian carcinomas. Positive controls of wild-type EDD embryonic mouse neural tissue ( Figure 4b ) and WT-30 cells (not shown) demonstrated intense nuclear staining, while no expression was seen in EDD null embryonic mouse neural tissue ( Figure 4a ). Of nine normal breast samples, four had no detectable expression and five had low-level expression of EDD ( Figure 4c ). Of 46 breast carcinomas, all expressed EDD and demonstrated either lowintensity (37%) or high-intensity (63%) nuclear staining ( Figure 4d ). Among the 94 serous ovarian carcinomas, 2% failed to express EDD while 59% had low expression ( Figure 4e ) and 39% had high EDD expression ( Figure 4f ). 
Mutation analysis of EDD in cell lines and tumours
To assess the frequency of mutations in the EDD gene in cancer, the complete coding region of the EDD mRNA (8397 nucleotides) was sequenced using cDNA derived from 26 breast, ovarian and prostate cancer cell lines. Three normal breast epithelial cell lines were also sequenced. A list of the sequence variants identified is shown in Table 2 . Only 2/25 cancer cell lines had variations in EDD mRNA that resulted in a change to the translated amino-acid sequence. These putative missense mutations were confirmed in the genomic sequence. The amino-acid changes were not in regions of the EDD protein with any obvious functional motifs and only the His4Asn change in the SK-Br-3 line alters amino-acid polarity. In the absence of matched normal DNA from the individuals from which the cell lines were derived, it is not possible to determine whether these represent true somatic mutations or rare polymorphisms. Few polymorphisms or silent substitutions were observed. Of the six conservative sequence variants, at least five are likely to be polymorphisms as they are found either in RNA derived from normal cell lines or tissues, or in multiple cell lines. A splice variant was also observed in all cell lines. The variant differs from the full-length EDD mRNA by deletion of 18 bp of (Figure 2 ), 37 breast cancers and 29 colon cancers confirmed the low frequency of mutation of the EDD gene, although only eight exons of EDD (covering approximately 13% of the coding sequence) were studied. These exons encode a nuclear localization signal (nt 1482-1598), a zinc-finger motif (nt 3573-3812) and the majority of the HECT domain (nt 7602-8339) (Henderson et al., 2002) . No mutations were found in the coding regions or splice junction sites of any cancer (data not shown).
Discussion
EDD is the human orthologue of the D. melanogaster 'hyperplastic discs' gene, which mutagenesis studies have shown has a critical role in control of cell proliferation during Drosophila development (Mansfield et al., 1994) , defining hyd as a tumour suppressor gene. This property suggests that the EDD gene might play a role in human cancer. Our interest in this possibility was strengthened by recent evidence that EDD interacts with one or more proteins in the DNA damage response (Henderson et al., 2002; Honda et al., 2002) . As an initial approach to evaluate EDD's involvement in cancer, we used microsatellite allelotyping to examine a narrow region of chromosome 8q that encompasses the locus for EDD (8q22.3) and identified this as a significant and specific area of allelic imbalance in ovarian cancer, hepatocellular carcinoma, squamous cell carcinoma of the tongue, breast cancer and metastatic melanoma. This was particularly evident in serous carcinoma of the ovary, where AI of the EDD locus occurred in 73% of cancers. Overexpression of either EDD mRNA or protein was observed in a significant proportion of breast and ovarian cancers and breast cancer cell lines, suggesting the possibility that EDD may be a target for amplification in this region of 8q.
Involvement of the 8q chromosomal arm is common in a wide variety of cancer types. Although several microsatellite analyses have interpreted the occurrence of AI of various 8q markers as evidence for loss of heterozygosity (LOH) (Iwabuchi et al., 1995; El-Naggar et al., 1997; Miyazaki et al., 1997; Dahiya et al., 1998) , amplification is a more likely explanation as CGH has only rarely detected 8q losses (Knuutila et al., 1999) . This is consistent with our quantitative PCR analysis, which demonstrates common increases in EDD and p53R2 gene copy number in cancer cell lines. Such chromosomal gains often indicate regions of amplification, arising during tumour progression, and which are presumed to include specific target oncogene(s). Multiplication or duplication of the entire 8q arm is also a common feature of many cancers, especially breast cancer (Kallioniemi et al., 1994; Mark et al., 1997; Sisley et al., 1997) , sometimes accompanied by 8p loss (isochromosome 8q) (van Dekken et al., 1997; Yokota et al., 1999) . While the majority of 8q amplicons encompass 8q24 where a likely target gene for amplification is the myc oncogene (8q24.12) (Yokota et al., 1999; Forozan et al., 2000; Savelyeva and Schwab, 2001) , CGH and microsatellite studies suggest that there are multiple amplicons on 8q at 8q21, 8q22-23 and 8q24 (Kallioniemi et al., 1994; Muleris et al., 1994; El-Naggar et al., 1997; Fejzo et al., 1998; Nupponen et al., 1999; Forozan et al., 2000; Seute et al., 2001) .
Evidence that the region of 8q containing EDD is a specific focus of chromosomal abnormality is particularly clear for serous carcinoma of the ovary in which the frequency of AI at the EDD gene-specific microsatellite CEDD was almost twice that of the most telomeric microsatellite examined. Ovarian carcinomas commonly show a high level of chromosomal rearrangement in comparison with other tumour types. This is subtype specific, with serous tumours displaying the greatest changes, endometrioid intermediate and mucinous cancers the least (Pieretti et al., 1995) , as was the case for AI at 8q in our study. In one study, the invasive potential of the serous subtype has been correlated with changes to chromosome 8 (Diebold et al., 1996) , although no correlation between clinical data (including grade and stage) and AI at 8q was found in our study.
Amplification is also common on 8q in hepatocellular carcinoma. Frequencies of AI (interpreted as LOH) vary from 26 to 77% (Nagai et al., 1997; Piao et al., 1998) , while CGH showed 8q gain in 100% of hepatocellular carcinoma arising from noncirrhotic liver (Wong et al., 1999) . In addition to frequent amplification at MYC, a discrete 8q22 amplicon was found in 3/30 cases of hepatocellular carcinoma (Fujiwara et al., 1993) , but little is known about the precise extent of these aberrations. Similarly, AI at 8q is common but poorly defined in head and neck cancer (Nawroz et al., 1994; Hermsen et al., 1997) and melanoma (Sisley et al., 1997; Parrella et al., 1999) . Although we only studied small numbers of these cancer types, we also confirmed the presence of common AI at 8q, and found that this often occurred in discrete regions at or adjacent to the EDD locus.
Given that EDD is commonly amplified in several cancer types and this often occurs within discrete amplicons that have telomeric boundaries that are located within 8q23, aberrations at the EDD gene locus cannot merely be ascribed to the presence of an extensive MYC containing amplicon or to 8q duplication. Even though this study showed that AI at EDD and MYC occurred at approximately the same frequency (38 and 42%, respectively), AI was only rarely continuous between these two loci, consistent with other studies where amplification was often discrete and discontinuous along 8q (Tsuneizumi et al., 2001) .
A likely consequence of EDD amplification is the frequent overexpression of mRNA that we have observed in breast carcinomas. Certainly, in breast cancer cell lines there is a strong trend for overexpression of EDD mRNA to occur in cells where EDD is amplified in the genome. Conversely, diploid cell lines rarely overexpressed EDD. Given that amplicons contain several genes with increased mRNA expression (Orntoft et al., 2002) , it was therefore not surprising to find another overexpressed gene (p53R2) in the proximity of EDD on 8q23. The involvement of p53R2 in the DNA damage response (Yamaguchi et al., 2001 ) also makes it an interesting candidate oncogene on 8q. In contrast, expression of carbonic anhydrase II (8q22) showed no correlation with gene copy number, indicating that only certain genes within this amplicon are regulated by this mechanism. Moreover, CA II mRNA was significantly reduced in most cancer cell lines compared to cell lines derived from the normal breast epithelium (data not shown). This is consistent with reports of reduced CA II expression in colorectal tumours (Nogradi, 1998) .
Consistent with the above data on gene amplification and mRNA overexpression, EDD protein is highly expressed in many breast carcinomas. Indeed, as is also the case for ovarian serous carcinomas, this appears to occur more frequently than can be accounted for by gene amplification, suggesting that additional mechanisms result in EDD protein upregulation. Similar observations have been made for cyclin D1 in breast cancers, where protein overexpression is significantly more common than gene amplification (Buckley et al., 1993) . Clearly, given that EDD is found only at low to very low levels in normal tissues, an important issue is to determine the functional consequences of EDD overexpression in cancer.
Despite the frequency of gross aberrations at the EDD locus and the common overexpression of the gene, sequencing of the large EDD mRNA (8397 nt) in a search for mutations revealed only 2/25 cancer cell lines with single nucleotide changes that result in amino-acid changes. These alterations might represent rare polymorphisms rather than mutations, as none of the changes were clearly disruptive and occurred in regions of the protein without any predicted functional significance. A splicing variant was found but this was present along with the unspliced transcript in every normal and cancer cell type examined. Similarly, SSCP analysis of a limited number of exons covering 13% of the coding region, and which code for putative functional domains, found no evidence of mutations in a series of breast, ovarian and colon cancers. This sequence conservation may point to a critical requirement for this gene in cell function, a conclusion reinforced by the hyd knockout lethality (Mansfield et al., 1994) and by our recent finding that targeted deletion of EDD in mice results in embryonic lethality accompanied by a generalized block in cell proliferation (Saunders et al., submitted). However, complex roles for these genes are likely. Although some hyd mutations result in imaginal disc hyperplasia (Mansfield et al., 1994) , consistent with a tumour suppressor gene function, other mutations result in retarded growth of the imaginal discs, suggesting that HYD might alternatively act as a positive regulator of cell proliferation. Lee et al. (2002) report that hyd null cells in the eye induce overgrowth of surrounding wild-type tissue but fail to proliferate themselves, an effect that appears to be mediated through activation of hedgehog and decapentaplegic signalling. Finally, in contrast to our data, a recent study found that EDD missense mutations were relatively common in microsatelliteunstable gastric and colorectal cancers, that is, cancers having deficient DNA mismatch repair (Mori et al., 2002) . In conclusion, there is mounting evidence from several studies that aberrations in EDD gene expression and presumably function are a common feature in many cancer types. Further studies are currently underway to gain a deeper understanding of the biological role of EDD and its potential involvement in tumorigenesis.
Materials and methods
Tumours and DNA extraction
Ovarian tumour tissue and matched blood or normal ovarian tissue adjacent to cancer were obtained from 98 patients and DNA extracted as described previously (Obata et al., 1998) . Metastatic melanoma tissue and matched blood or normal skin tissue were obtained from 20 patients and DNA isolated as reported previously (Indsto et al., 1998) . DNA was extracted from matched normal liver and hepatocellular carcinoma tissue samples microdissected from 19 primary liver tumours (Macdonald et al., 1998) . For AI analysis, paraffin-embedded breast cancer tissues and normal blood were obtained from 24 patients. Tumour location was determined by haemotoxylin and eosin staining and cells were microdissected from 4-5 adjacent sections. DNA was extracted in lysis buffer (0.45% Tween 20, 5 mg/ml proteinase K, 0.25% BSA) at 551C for 8 h, then boiled for 10 min. DNA was extracted from blood using a Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN, USA).
For RT-PCR, breast cancer samples were collected at the time of surgery. Normal breast tissue (based on histological examination) was removed from unaffected regions of the excised cancer.
Paraffin-embedded archival samples from 12 squamous cell carcinoma of the anterior tongue and matched lymph nodes were from a series described by Bova et al. (1999) . Areas of malignant squamous cells were identified by a pathologist from haemotoxylin and eosin stained slides and were microdissected from unstained adjacent 10 mm sections under a light microscope. Normal tissue was gained from uninvolved lymph nodes and/or microdissected from areas of normal cells surrounding the squamous cell carcinoma. Samples were digested in 250 ml of proteinase K (2 mg/ml) for 5 days at 371C with constant agitation. The digest was then extracted once with phenol, once with chloroform, and DNA precipitated in ethanol overnight and redissolved in 30 ml of TE buffer ('microdissected DNA').
The study proceeded following approval from the St Vincents Hospital Human Research Ethics Committee.
Isolation and cloning of EDD-linked microsatellites CEDD and 586F18b
A human P1 genomic library (Incyte Genomics, CA, USA) was screened with two cDNA probes covering 4 kb of the EDD coding sequence (Callaghan et al., 1998) . DNA from positive clones was extracted, digested with HincII, separated by gel electrophoresis and rescreened by Southern blotting using an oligonucleotide probe (CA) 15 . Positive genomic DNA fragments were cloned into pBluescript and sequenced and the resulting data identified a novel dinucleotide repeat microsatellite CEDD. Unique primers were designed around the microsatellite to give a product of approximately 220 bp; CEDD forward 5 0 -TACCCTGCAGTAAAATCTCACATG-TACTCCC-3 0 , CEDD reverse 5 0 -AGAATCGCTTGAACC-TAGTAGGTGAAGGTG-3 0 . Subsequently, EDD genomic sequence became available (Genbank Accession: AC021004) and CEDD was located in an intron between bases 2616 and 2617 of the EDD coding sequence. The minimum size of the EDD gene is 100 kb, consisting of at least 46 exons. Within the same genomic clone, another EDD-specific dinucleotide repeat microsatellite was identified and named 586F18b. Unique primers were designed around this microsatellite to give a product of approximately 200 bp; forward 5 0 -GCT AGG GAA CCA AAC TGC CAG -3 0 , reverse 5 0 -TGC AAA ATA ACA ATA GCTTTG CTT AG-3 0 . 586F18b is located in an intron between bases 6631 and 6632 of the EDD coding sequence. CEDD and 586F18b were 43 and 55% heterozygous, respectively, in a collection of DNA from 20 human cell lines (data not shown).
Microsatellite analysis of allelic imbalance
Allelic imbalance is defined as the relative gain or loss of one allele when genomic DNA from tumour and matching normal tissue is compared. AI is indicative of either gene amplification or LOH of an allele and (presumably) the surrounding chromosomal region. The frequency and distribution of AI on 8q22.3-24.13 was determined by microsatellite analysis, which allows comparison of alleles (microsatellites) that consist of variable numbers of short repetitive sequences, that is, CEDD, 586F18b and seven other dinucleotide and tetranucleotide repeat polymorphic markers mapped in this region (Genome Database, www.gdb.org/) (Figure 1) . CEDD, D8S326, D8S257, D8S300, D8S545 and D8S85 were used for analysis of ovarian cancers, hepatocellular carcinoma, metastatic melanoma and squamous cell carcinoma of the tongue. The additional markers 586F18b, MYC-PCR.3 and D8S198 were used for analysis of breast cancers. Primer pairs were obtained from Research Genetics (Huntsville, AL, USA) and Pacific Oligos (Lismore, Australia). Ovarian DNA was analysed by radioisotope-based methods as previously described (Obata et al., 1998) . For DNA from other tissues, in each PCR reaction the forward primer was labelled with either 6-FAM or TET fluorescent label. Reactions were performed using 40-60 ng of DNA from hepatocellular carcinoma and metastatic melanoma, 1 ml of breast cancer extracted DNA or 2-3 ml of microdissected DNA from squamous cell carcinoma of the tongue. The PCR reaction components were as follows: 10 mm Tris-HCl, pH 8.3; 50 mm KCl; 66 mm dNTP mix; 1.5 mm MgCl 2 ; 5 pmol of both forward and reverse primer and 0.8 U of Amplitaq Gold DNA polymerase (Applied Biosystems, Sydney, Australia). PCR conditions for microsatellites D8S326, D8S257, D8S545, D8S85, D8S198 and MYC-PCR.3 were: 12 min hotstart 951C; 35 cycles (40 for microdissected DNA) of (1) 941C 15 s, (2) 601C 15 s (661C for CEDD, 521C for 586F18b) and (3) 721C 30 s; 5 min 721C; 41C hold. Amplification of the CEDD microsatellite from microdissected DNA required a 30 s annealing step, a 1 min extension step, and 35 cycles. Amplification of the microsatellite D8S300 was performed as follows: 12 min hotstart 951C; 35 cycles of (1) 941C 30 s, (2) 601C 30 s and (3) 721C 60 s; 5 min 721C; 41C hold. No PCR products could be obtained from DNA recovered from paraffin-embedded tongue carcinoma with D8S300 primers, presumably because of DNA shearing.
Duplicate fluorescent products were separated on an ABI 377 DNA Sequencer (Applied Biosystems) and analysed using Genescan and Genotyper software (Applied Biosystems). Ambiguous results were resolved on separate gels. The abundance of each heterozygous allele of a microsatellite was measured as a fluorescence peak area, and relative abundance was then calculated. AI was defined by a reproducible reduction in relative abundance of an allele between normal and cancer DNA. A 30% reduction threshold was used as previously described for the cohort of melanoma samples (Indsto et al., 1998) , although for some samples, AI was considered to be probable when a 20-30% reduction was reproducibly found. A 30% threshold was also used for breast and hepatocellular cancers. A difference of 50% or more was considered to represent AI in squamous cell carcinomas of the tongue due to a lower level of normal cellular DNA contamination in these samples.
FISH
Two P1 plasmids encoding approximately 100 kb of EDD genomic sequence used for FISH were nick-translated with biotin-14-dATP and hybridized at a final concentration of 20 ng/ml to metaphases from the breast cancer cell lines MDA-MB-436, SKBR-3, BT-20 and BT-483. The single copy FISH method was modified from that previously described (Callen et al., 1990) in that chromosomes were stained before analysis with both propidium iodide (as counterstain) and DAPI (for chromosome identification). Images of metaphase preparations were captured by a CCD camera using the ChromoScan image collection and enhancement system (Applied Imaging, Newcastle, UK).
Quantitative RT-PCR -breast tissue
RNA was extracted from samples using Trizol reagent (Life Technologies, Paisley Scotland, UK). Reverse transcription was performed, followed by quantitative PCR using a Taqman-based methodology as previously described (AlTaher et al., 2000) . PCR primers for EDD were designed within 300 bases of the polyA addition site. The sequences of EDD-specific primers were: forward EDD-407F GCTA-GTCACCAACTTCTGGGTCTAA; reverse EDD-490R CAGCAAAAAGATAAATCACAGTGTAAATT; fluorescent probe EDD-433 T FAM-CCCAGCCAAAGATGA-CAGCAGAACAAC-TAMRA. Results are expressed as copies of EDD cDNA/3 Â 10 9 per sample, corrected for relative expression of the housekeeping gene translation initiation factor 2B (IF2B).
Quantitative PCR and RT-PCR -breast cancer cell lines
Cells (approximately 5 Â 10 7 ) harvested from duplicate 150 cm 2 flasks were pooled and RNA was extracted using the RNeasy RNA extraction kit (Qiagen, Melbourne, Australia GAPDH, forward GACATCAAGAAGGTGGTGAA, reverse TGTCATACCAGGAAATGAGC. All primer pairs spanned at least one intron, and products were visualized on an agarose gel to confirm product size. Relative expression of all genes was corrected for cDNA concentration using GAPDH expression.
DNA was extracted from the above cell lines using a DNA extraction kit (Stratagene, Sydney, Australia). PCR reactions to determine genomic copy number utilized the reverse primer from above (unless mentioned). Primers for: EDD, forward CATTGCTGACCCTATCCCTGTGTTG, reverse TAGCCCGTGAAATCCTCCCATCTC; CA II, forward ACCCGCCTCATGCCTCAGCCTTAC; p53R2, forward TGTCAGCCTTGAGTACCTCCAGGG; beclin, forward TAGGTTTGGGGTGAGAGTGG, reverse AGTCTG-TGGGCAGCAAGG. All products were visualized on an agarose gel to confirm product size. Relative DNA copy number was corrected using known beclin gene copy number determined by FISH (Aita et al., 1999) .
EDD mRNA sequence analysis
Total RNA was extracted from the following human cell lines using the RNeasy Maxi Kit (Qiagen): breast cancer MDA-MB-468, MDA-MB-436, MDA-MB-231, MDA-MB-453, MDA-MB-175, MDA-MB-361, MDA-MB-134, MDA-MB-157, BT-20, T-47D, BT-549, BT-483, MCF-7, BT-474, SK-Br-3, ZR-75-1, Hs 578T; normal breast epithelium HBL-100 (SV-40 transformed), 184, HMEC 219-4; ovarian cancer OVCAR-3, OVCA-420, IGROV-1, SKOV3, A2780; prostate cancer PC-3, DU-145, LnCaP. cDNA was synthesized using the Expand Reverse Transcriptase System (Boehringer Mannheim, Sydney, Australia). In all, 2 mg of total RNA and 2 ml oligo dT (Boehringer Mannheim) was made up to 22 ml with water, heated at 651C for 10 min and cooled on ice followed by addition of 8 ml Expand Reverse Transcriptase buffer (5 Â ; 250 mm Tris-HCl, 200 mm KCl, 25 mm MgCl 2 , 2.5 % Tween 20 (v/v), pH 8.3), 1 mm each dATP, dCTP, dGTP and dTTP, 10 mm DTT and 2 ml (100 U) Expand Reverse Transcriptase. The reverse transcriptase reaction was then performed at 421C for 45-60 min. A total of 10 PCR products were designed to cover the entire 8.5 kb coding region of the EDD gene. PCR reactions included 3 ml of the reverse transcriptase reaction, 10 pmol of each primer, 1.75 U Expand High Fidelity DNA polymerase (Boehringer) and 1.5 mm MgCl 2 . Amplification was carried out using the following protocol: 2 min denature at 941C; 10 cycles of 30 s denature, 30 s annealing and 60 s extension at 721C; 24 cycles of 30 s denature, 30 s annealing and 60 s extension with a 5 s increase per cycle; 5 min extension. Annealing temperatures depended on the primers used (primer sequences available on request). PCR products were purified using the QIAquick PCR purification system (Qiagen) and quantitated by visualization on a gel. Sequencing reactions were performed at the Australian Genome Research Facility (Brisbane, Australia) and sequence analysis and assembly were performed using Editview and Autoassembler software, respectively (Applied Biosystems).
Single-stranded conformation polymorphism analysis
Single-stranded conformation polymorphism analysis (SSCP) analysis was performed as previously described (Campbell et al., 1994) on eight exons of EDD-encoding regions of potential functional significance, that is, the HECT domain, nuclear localization signal and zinc-finger motif. Primers were designed within intronic sequence to generate PCR products of 200-300 bp.
EDD immunohistochemistry
Immunohistochemistry (IHC) was performed on paraffinembedded, formalin-fixed breast (nine normal breast and 46 breast cancers) and ovarian tissues (94 ovarian cancers). Paraffin-embedded embryonic neural tissues from wild-type and EDD D/D (knockout) mice (Saunders et al., submitted) were used as positive and negative controls, respectively. Paraffinembedded cell pellets from the WT-30 cell line, which overexpresses EDD (Henderson et al., 2002) , were used as an additional positive control.
For EDD IHC, sections were dewaxed and rehydrated before unmasking in target retrieval solution (high pH: DAKO Corporation, Carpenteria, CA, USA) in a waterbath, at 1001C for 30 min.
Using a DAKO autostainer, endogenous peroxidase activity was quenched in 3% hydrogen peroxide in methanol, endogenous avidin and biotin were blocked with an avidin biotin block (DAKO Corporation) and nonspecific binding of secondary antibody was blocked by incubation with a serumfree protein block (DAKO Corporation). Sections were incubated for 30 min with 1 : 150 anti-EDD (M19) antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and subsequently for 15 min with 1 : 200 biotinylated horse antigoat (Vector Laboratories, Burlingame, CA, USA). A streptavidin-biotin peroxidase detection system was used according to the manufacturer's instructions (Vectastain Elite kit; Vector Laboratories) with 3,3'-diaminobenzidine as substrate. Counterstaining was performed with Mayer's haematoxylin (DAKO Corporation).
The degree of staining was assessed by two separate observers, and discrepancies were resolved by conferencing. EDD expression scores were determined by combining the percentage of cells expressing EDD (range of 1-4 for 1-100% cells stained) and intensity of staining (range of 0-3). A combined score of 0 was called no expression, a score in the range of 1-5 was low expression and a score of 6 and 7 was called high expression.
Abbreviations AI, allelic imbalance; CA II, carbonic anhydrase II; CEDD, CA repeat within EDD; CGH, comparative genomic hybridization; EDD, E3 isolated by differential display; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; LOH, loss of heterozygosity; MI, microsatellite instability; p53R2, p53 ribonucleotide reductase; SSCP, single-stranded conformational polymorphism.
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